APEX Biologix Expands its Footprint Through Investment by Desert Highlands Regenerative Merger enables an increased focus on product innovation, more cutting-edge regenerative medicine research and strategic collaborations with other complementary technology companies. News provided by Share this article Share this article SALT LAKE CITY, April 16, 2021 /PRNewswire/ -- Desert Highlands Regenerative (DHR), a private equity group, has acquired a majority ownership of APEX Biologix (APEX), the designers and manufacturers of the XCELL Platelet-Rich Plasma (PRP) and other regenerative medicine products. APEX Biologix also appointed to its senior management team Jeff Frey as Chief Commercial Officer. Jeff's orthopedic and regenerative medicine experience spans 25 years with companies such as Johnson & Johnson Orthopedics, Integra Lifesciences, and Ortho Solutions.